Last reviewed · How we verify
DSP-5423P Placebo-to-Flex — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
DSP-5423P Placebo-to-Flex (DSP-5423P Placebo-to-Flex) — Sumitomo Pharma Co., Ltd.. DSP-5423P Placebo-to-Flex's mechanism of action is currently unknown.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DSP-5423P Placebo-to-Flex TARGET | DSP-5423P Placebo-to-Flex | Sumitomo Pharma Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DSP-5423P Placebo-to-Flex CI watch — RSS
- DSP-5423P Placebo-to-Flex CI watch — Atom
- DSP-5423P Placebo-to-Flex CI watch — JSON
- DSP-5423P Placebo-to-Flex alone — RSS
Cite this brief
Drug Landscape (2026). DSP-5423P Placebo-to-Flex — Competitive Intelligence Brief. https://druglandscape.com/ci/dsp-5423p-placebo-to-flex. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab